Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,230.12
(
0.29%
)
US TECH 100
26,942.00
(
0.87%
)
Dow Jones
49,499.27
(
-0.31%
)
Brent Oil
107.80
(
0.00%
)
Bitcoin
78,285.96
(
0.12%
)
News Focus
News Focus
Post# of 447734
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

io_io

Send PM Follow Ignore
Followers 63
Posts 5557
Boards Moderated 0
Alias Born 01/17/2005

io_io

Re: Biobillionair post# 240815

Monday, 01/13/2020 10:32:55 PM

Monday, January 13, 2020 10:32:55 PM

Post# of 447734

Current case does not argue composition patents because there is no argument ... the generics would directly infringe on Vascepa composition patents...see stipulated facts. The composition patents are enough to bar launch of Vascepa composition in any indication.

Pump away, but I already addressed that to you here.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent AMRN News
More AMRN News